BrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral
Rhea-AI Summary
BrainsWay (NASDAQ & TASE: BWAY) announced a strategic minority-stake investment in Sound Minds Behavioral, an outpatient behavioral health platform with locations across Connecticut, Pennsylvania, New Jersey and New York. BrainsWay will invest $500,000 in Sound Minds through a preferred, annually compounding security.
According to BrainsWay, the deal supports its strategy of partnering with growth-oriented mental health providers to expand access to interventional psychiatry and innovative, evidence-based care. The transaction was executed with CM Counsel Management LLC, d/b/a Sound Minds Behavioral, with S. Friedman, Abramson & Co. Law Offices advising BrainsWay.
Positive
- $500,000 minority investment in Sound Minds Behavioral via preferred security
- Supports BrainsWay’s strategy to partner with growth-oriented mental health providers
Negative
- None.
News Market Reaction – BWAY
In the Jul 16 session, BWAY declined 0.34%, reflecting a mild negative market reaction. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 29 | Clinical data update | Positive | +4.8% | Positive real-world Deep TMS data in PTSD and major depressive disorder. |
| Jun 22 | Coverage expansion news | Positive | -3.4% | Expanded U.S. medical policy coverage for accelerated Deep TMS protocols. |
| Jun 09 | Clinical data presentation | Positive | -0.9% | New 12-month durability data for SWIFT accelerated Deep TMS in MDD. |
| May 18 | Minority-stake investment | Positive | -1.0% | Minority preferred, annually compounding stake in Hopemark Health platform. |
| May 13 | 1Q26 earnings report | Positive | -2.6% | Strong Q1 2026 growth in revenue, profitability, and installed Deep TMS base. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows multiple positive announcements followed by negative next-day moves, with only one clear aligned upside reaction.
Key Terms
interventional psychiatry medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health providers to raise awareness and expand access to transformative care
BURLINGTON, Mass. and JERUSALEM, July 16, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced its participation in a strategic equity financing round with Sound Minds Behavioral, a leading growth-oriented outpatient behavioral health platform with multiple locations throughout Connecticut, Pennsylvania, New Jersey and New York (“Sound Minds Behavioral” or “Sound Minds”). Under the terms of the agreement, BrainsWay will invest
“We are excited to add Sound Minds as a partner in our strategic initiative to expand access to transformative care via interventional psychiatry solutions. Our minority stake approach continues to facilitate our partners’ expansion through growth capital while enabling us to maintain our core focus on the scientific and clinical advancement of our technology and delivering best-in-class support to all of our customers,” said Hadar Levy, BrainsWay’s Chief Executive Officer.
“We are excited to partner with BrainsWay as we continue to build the leading outpatient behavioral health platform in the Mid-Atlantic,” said Jordan Klear, Chairman and Chief Executive Officer of Sound Minds Behavioral. “BrainsWay brings far more than capital; they understand the interventional psychiatry landscape and share our vision of expanding access to innovative, evidence-based care. We believe this partnership will help support our continued growth while enhancing the cutting-edge mental health treatments that we provide to our patients.”
The investment transaction was made with CM Counsel Management LLC, d/b/a Sound Minds Behavioral. Advocates Ami Hordes and Sarit Molcho of S. Friedman, Abramson & Co. Law Offices served as lead counsel for BrainsWay on the transaction as well as on the Company’s prior minority stake investments.
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
About Sound Minds Behavioral
Sound Minds Behavioral is the leading growth-oriented outpatient mental health platform in the Mid-Atlantic with multiple locations throughout Connecticut, Pennsylvania, New York, and New Jersey. Sound Minds provides therapy, medication management, PHP/IOP, and interventional psychiatry services across its geographical footprint. The organization is focused on expanding access to evidence-based mental health care while investing in scalable clinical operations, clinical partnerships, and interventional psychiatry services across its growing footprint. For more information, please visit Sound Minds Behavioral.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words, and also includes any financial guidance and projections contained herein. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the failure of our investments in management services organizations and/or other clinic-related entities to produce profitable returns; inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements.
Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission.
Contacts:
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com
Investors:
Brian Ritchie
LifeSci Advisors LLC
britchie@lifesciadvisors.com
